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In vitro analysis of promoter activity in Müller cells
Scott F. Geller,1 Phillip S. Ge,1,2 Meike Visel,1 John G. Flannery1,2,3
1Helen Wills Neuroscience Institute; 2Department of Molecular and Cell Biology; 3Department of Vision Science, University of
California, Berkeley, CA
Purpose: Rational modification of promoter architecture is necessary for manipulation of transgene activity and requires
accurate deciphering of regulatory control elements. Identification of minimally sized promoters is critical to the design
of viral vectors for gene therapy. To this end, we evaluated computational methods for predicting short DNA sequences
capable of driving gene expression in Müller cells.
Methods: We measured enhanced green fluorescent protein (eGFP) expression levels driven by “full-length” promoters,
and compared these data with computationally identified shorter promoter elements from the same genes. We cloned and
screened over 90 sequences from nine Müller cell-associated genes: CAR2, CD44, GFAP, GLUL, PDGFRA, RLBP1,
S100B, SLC1A3, and vimentin (VIM). We PCR-amplified the “full-length” promoter (~1500 bp), the proximal promoter
(~500 bp), and the most proximal evolutionarily conserved region (ECR; 95–871 bp) for each gene, both with and without
their respective 5′ untranslated regions (UTRs), from C57BL/6J mouse genomic DNA. We selected and cloned additional
ECRs from more distal genomic regions (both 5′ and 3′) of the VIM and CD44 genes, using both mouse and rat (Sprague-
Dawley) genomic DNA as templates. PCR products were cloned into the pFTMGW or pFTM3GW lentiviral transfer
vectors. Plasmid constructs were transfected into rat (wMC) or human (MIO-M1) Müller cells, and eGFP expression
levels were evaluated by fluorescence microscopy and flow cytometry. Selected constructs were also examined in NIH/
3T3 and Neuro-2a cells.
Results: Several ECRs from the nine Müller cell-associated genes were able to drive reporter gene expression as well as
their longer counterparts. Preliminary comparisons of ECRs from the VIM and CD44 genes suggested that inclusion of
UTRs in promoter constructs resulted in increased transgene expression levels. Systematic comparison of promoter activity
from nine Müller cell-expressed genes supported this finding, and characteristic regulation profiles were evident among
the different genes tested. Importantly, individual cloned promoter sequences were capable of driving distinct levels of
transgene expression, resulting in up to eightfold more cells expressing eGFP with up to 3.8-fold higher mean fluorescence
intensity (MFI). Furthermore, combining constructs into single regulatory “units” modulated transgene expression,
suggesting that secondary gene sequences provided in cis may be used to fine-tune gene expression levels.
Conclusions: In this study, we demonstrate that computational and empirical methods, when used in combination, can
efficiently identify short promoters that are active in cultured Müller cells. In addition, the pFTM3GW vector can be used
to study the effects of combined promoter elements. We anticipate that these methods will expedite the design and testing
of synthetic/chimeric promoter constructs that should be useful for both in vitro and in vivo applications.
Therapeutic treatment of dominant disease in the human
retina has yet to be attempted. Given the extreme
heterogeneity of retinal diseases (RetNet), effective therapies
will likely require more sophisticated vector designs than are
currently available for gene augmentation of recessive null
mutations. One of the major challenges in engineering any
genetic therapy is to design a transgene cassette that enables
precise regulatory control of gene expression while abiding
by the size constraints of the virus’ packaging limit.
Expression of transgenes by targeted cells requires
coordination of gene delivery, nuclear localization, and
subsequent harnessing of the cell’s transcriptional machinery.
Though viral targeting of retinal cells has improved in recent
years [1,2], a critical aspect of any gene therapy is how to
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control the specificity and expression levels of the gene
product being expressed [3] once it is delivered to the proper
cell.
Progress in achieving precise control over transgene
expression is hampered by an incomplete understanding of the
underlying genetic mechanisms influencing endogenous gene
expression [4]. In recent years, numerous promoters have
been characterized and used to confer inducible, constitutive,
cell specific, as well as temporal transgene expression to
retinal (and many other) cells. However, experimental gene
augmentation strategies often utilize strong, constitutive
promoters for driving transgene expression in retinal
photoreceptors, retinal ganglion cells, and pigmented
epithelial cells [5–7]. There is concern that promiscuous,
high-expression promoter elements, such as cytomegalovirus
(CMV) and chicken beta actin (CBA) [6,7], can generate
undesirable and toxic gene expression, particularly when
“bioactive” molecules are delivered. Although robust gene
expression is often preferable for reporter gene-associated
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assays used in the laboratory, improved precision and control
of gene expression levels will be crucial for human therapies.
To this end, novel approaches are being considered for
controlling expression levels in diverse cellular contexts [8,
9], and synthetic control over viral transgene expression in
retinal gene therapy applications is now feasible [10–14].
In addition to imparting improved control overexpression
levels, it is critical to identify promoters that are small enough
to be efficiently packaged into viral capsids [15]. For example,
adeno-associated virus (AAV), which has a relatively small
(~4.7 kb) packaging limit [16], continues to be the most
widely considered virus for treating eye disease [5,7]. There
are currently no reliable methods for predicting how the
primary gene sequence and nuclear microenvironment(s)
combine to direct, control, and regulate gene expression [17].
Nevertheless, recent advances in computational genomics
have provided valuable tools for cross-genome data mining,
and have made promoter selection less empirical [18–20].
These online bioinformatics tools generally provide
alignments of whole genes as well as chromosomes and allow
for rapid identification of evolutionarily conserved regions
(ECRs): small stretches of genomic DNA (gDNA) that have
survived prolonged selective pressure and presumably
contribute to proximate gene expression. These sequences
typically contain conserved, empirically annotated
transcription factor binding sites, which likely contribute to
mRNA expression by influencing both expression levels and
cellular specificity [18,21]. Therefore, identification of ECRs
from regulatory regions of genes with restricted expression
patterns, i.e., in a targeted cell type, is a logical starting point
in the search for compact promoters for viral gene therapy.
Previously [22] we modified a self-inactivating lentiviral
(LV) transfer vector, pFUGW [23,24], to facilitate the
throughput, cloning, and evaluation of novel, computationally
identified promoter constructs. In the current study, promoters
and ECR promoter fragments from nine Müller cell-
associated genes were cloned into our modified vector
(pFTM3GW) and studied by transfection and flow cytometry
(accession numbers refer to Mus musculus genes): carbonic
anhydrase II (CAR2;NM_009801) [25]; CD44
(NM_009851) [26]; glial fibrillary acidic protein
(GFAP;NM_010277) [27]; glutamate-ammonia ligase
(GLUL;NM_008131; historically referred to as glutamine
synthetase, GS) [28]; platelet derived growth factor receptor,
alpha polypeptide (PDGFRA;NM_011058) [29];
retinaldehyde binding protein 1 (RLBP1;NM_020599) [30];
S100 protein, beta polypeptide, neural (S100B;NM_009115)
[31,32]; solute carrier family 1 (glial high affinity glutamate
transporter), member 3 (SLC1A3;NM_148938; historically
referred to as glutamate-aspartate transporter, GLAST) [33,
34]; and vimentin (VIM;NM_011701) [35].
METHODS
Vector design: We modified a LV transfer vector (pFTMGW)
[22] by adding restriction sites and enhancing the multiple
cloning site (MCSv3); the new vector was named pFTM3GW
(Figure 1). Briefly, we replaced the original multiple cloning
site (MCS) in pFTMGW with MCSv3, in which the order of
the 12 unique restriction sites was modified (5′-PacI-AsiSI-
BlpI-RsrII-SwaI-AscI-HpaI-BsiWI-SdaI-NheI-BstEII-
BamHI-3′) to facilitate double-digestion reactions (the BsiWI
site was newly added). In addition, we flanked the
transcription blocker (TB) with an additional BstBI restriction
site, facilitating rapid removal of the TB before LV
production. Finally, the hCMV/LTR hybrid promoter was
modified such that it was flanked by SpeI endonuclease sites,
allowing for efficient removal during preliminary candidate
promoter evaluation, if desired.
Candidate sequence selection: Using online bioinformatics
software (dcode) we identified and cloned full-length
promoters (~1500 bp), proximal promoter regions (500 bp),
and the most proximal ECRs, relative to the transcription start
site (TSS), for each of nine Müller cell expressed genes:
CAR2, CD44, GFAP, GLUL, PDGFRA, RLBP1, S100B,
SLC1A3, and VIM. ECR sequences were identified in
canonical promoter regions mandating a minimum of 70%
sequence homology between human and mouse genomes over
a 100 bp “window.” Based on the observation that several
genes have sizable 5′ untranslated regions (UTRs) containing
numerous transcription factor binding sites, in addition to the
fact that 5′ UTRs afforded improved expression in first-
generation constructs, fragments from each of the nine genes
(1500 bp, 500 bp, and ECR) were cloned with and without
their associated 5′ UTR, or part thereof (see Appendix 1). All
transcription start sites were identified using RefSeq
sequences (NCBI) compiled into single data files available at
(ECRbase). The current mouse (mm8), rat (rn4), and human
(hg18) assemblies of their respective genomes were used for
all sequence comparisons, alignments, and primer design.
Sequence analysis and primer design: DNA sequences
identified using the ECR Browser were imported into Vector
NTI (VNTI; Invitrogen, Carlsbad, CA). Primers were selected
using VNTI primer design software, and one or two restriction
sites were manually added to the 5′ ends of each primer to
confer additional flexibility in the cloning process and to allow
constructs to be cloned into different regions of the MCS in
the pFTM3GW vector (see Appendix 1 and Appendix 2).
Primers from Operon Technologies (Huntsville, AL) were
resuspended at 100 µM in 10 mM Tris (pH 8.0) and 1 mM
EDTA.
Polymerase chain reaction amplification and cloning:
Sequences were PCR-amplified from C57BL/6J mouse or
Sprague-Dawley rat gDNA using 0.5 U per reaction Platinum
Taq or Platinum Taq High-Fidelity Polymerases (Invitrogen).
Standard reaction conditions were 2.5 mM Mg2+, 0.2 µM each
primer, 0.2 mM deoxyribonucleotide triphosphates (dNTPs),
and 10–50 ng gDNA in a 20 µl reaction volume. A list of
cloned sequences, including their primer sequences and their
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respective chromosomal locations, are shown in Appendix 1
and Appendix 2. PCR products were typically T/A cloned into
the pGemT-Easy vector (Promega, Madison, WI) and
transformed into DH5alpha chemically competent cells
(Invitrogen). Plasmid DNA was isolated using the QIAprep
Miniprep Kit (Qiagen Corp., Valencia, CA). Each promoter
fragment was digested and gel purified from pGem-T-easy,
and subsequently subcloned into linearized pFTM3GW. For
verification, all constructs were PCR screened, endonuclease
digested, and sequenced. While most promoter sequences
matched published database sequences exactly, some
sequences had individual point mutations as well as small (1
or 2 bp) insertions or deletions, particularly in genomic
regions containing a minisatellite repeat(s).
Cell culture and transfection: Cell culture was performed as
previously described [22] for both rat (wMCs) and human
(MIO-M1) Müller cells [36]. MIO-M1 cells were a gift from
University College London. NIH/3T3 (ATCC#: CRL-1658)
and Neuro-2a (ATCC#: CCL-131) were obtained from the
University of California, Berkeley core research facility.
Briefly, approximately 200,000 Müller cells or 400,000 NIH/
3T3 or Neuro-2a cells were plated per well on 12 well plates.
Cells were grown in Dulbecco's Modified Eagle's Medium
(DMEM) including high glucose (Invitrogen) with 10% fetal
bovine serum (FBS; HyClone; Thermo Fisher Scientific,
Waltham, MA) and 4 mM L-glutamine without antibiotics
until they reached 90% confluence (~24 h). A transfection
complex with 0.75 µg plasmid DNA (experimental or control)
and 3.75 µl Lipofectamine 2000 (Invitrogen) in 200 µl of
OptiMEM (Gibco; Invitrogen) medium was prepared
according to the manufacturer’s specifications. Growth
medium was removed and the transfection complex was
added into each individual well. After 10 min, 1 ml of fresh
media without antibiotics was added. Cells were cultured for
approximately 40 h before flow cytometry analysis.
Flow cytometry and data analysis: Methods for flow
cytometry and fluorescence microscopy were described
previously [22]. Briefly, transfected wMC and MIO-M1
Müller cells were trypsinized for ~3–5 min, resuspended in
500 µl DMEM media, and maintained on wet ice. At least
20,000 cell counts were collected for each sample, and three
independent samples were counted for each construct. Mean
fluorescence intensity (MFI) and percent eGFP positive cells
were calculated and collected for each sample under identical
gating conditions within each experiment. All data were
normalized to the promoter-less parent vector (pFTMGW or
pFTM3GW) or pFUGW, and were subsequently plotted as
relative fold-change in terms of number of eGFP labeled cells
and MFIs. pFTM3GW and pFTMGW [22] employ a TB
element to minimize (by 85%–90%) transgene expression by
an upstream hybrid CMV/5′LTR promoter, which is
necessary for virus production. The fortuitous “leakiness” of
Figure 1. The pFTM3GW lentiviral
transfer vector. The pFTM3GW
plasmid vector was constructed by
adding restriction sites to the parent
plasmid, pFTMGW. A SpeI site was
added to the 5′ end of the hCMV
enhancer, and a BstBI site was added to
the 3′ end of the TB; both modifications
duplicate existing sites on the opposite
sides of the genetic elements,
simplifying removal of the elements
when desired. We also reordered the
restriction sites in the multiple cloning
site (MCS) to facilitate double-digestion
reaction performance and subsequent
cloning. ColE1 ori (bacterial origin of
replication) and AmpR (ampicillin
resistance gene) were used for plasmid
replication. The enhanced green
fluorescent protein (eGFP) is the
reporter molecule. The cytomegalovirus
promoter (CMV), long-terminal repeats
(LTRs), splice donor and viral
packaging sequences (SD/Psi), Rev
Response element (RRE), central
polypurine tract (CPPT) and
Woodchuck hepatitis virus post-
transcriptional regulatory element
(WPRE) are viral elements.
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the TB element has two benefits: 1) it allows for efficient and
accurate normalization across experiments; and 2) it allows
for the identification of MCS-cloned elements that negatively
influence transgene expression. We used Microsoft Excel for
all statistical analyses, using the Student's t-test for all
comparisons (two-sample assuming equal variances).
Analyses were performed on raw data counts and collected as
percent positive cells (fluorescent, flow cytometry counted).
Data and errors were normalized to the promoter-less parent
vectors (pFTMGW or pFTM3GW) or pFUGW. Data obtained
from control plasmid transfections were set to a value of 1.0
(or 100%), which allowed for relative fold-change (increase
or decrease) calculations for experimental constructs, as well
as a baseline for comparison between experiments. All error
bars represent (±) 1 standard deviation.
Microscopy: For microscopic examination of eGFP
expression, cells were grown on cover glass under identical
conditions, and were processed as previously described [22].
Briefly, cells were transfected for approximately 24 h, rinsed
with phosphate buffered saline (PBS; pH 7.4), fixed with 10%
neutral buffered formalin for 15 min, rinsed again with PBS,
and inverted on a microscope slide containing a drop of
Vectashield (Vector Laboratories, Inc., Burlingame, CA)
containing DAPI (4',6-diamidino-2-phenylindole) as a
Figure 2. Flow cytometry analysis of
promoter fragments from nine Müller
cell expressed genes. A: Diagrammatic
representation of DNA fragments
analyzed here and in subsequent figures.
B-J: Significant variability in both
number of positive cells and
fluorescence intensity are apparent
among the 61 fragments tested. Seven
fragments were analyzed for each gene:
the 5′ UTR alone (yellow), a ~1500 bp
(red), a ~500 bp (green), and a variable-
sized evolutionarily conserved region
(ECR; blue), each with and without their
respective 5′ UTRs. Bars indicate fold
change in number of eGFP positive
cells, normalized to the promoter-less
parent vector (pFTM3GW). The mean
fluorescence intensity (MFI) for each
construct was also normalized to the
parent vector (pFTM3GW) and is
shown immediately below each bar
(shown in orange). UTRs for the
GFAP (14 bp) and CAR2 (28 bp) genes
were quite short and not individually
tested. Both the locationrelative to the
transcriptional start site (TSS), and the
size of the ECRs vary for each gene
(official gene names can be found in
Introduction). Refer to Appendix 1 for
genomic coordinates of each construct.
The symbol (§) identifies ECRs that
were not immediately adjacent to the
TSS (CD44, GFAP, RLBP1, and VIM),
and less-conserved DNA between the
ECR and TSS was included for each of
these constructs. ATG is the codon for
the starting methionine. Error bars
represent 1 standard deviation. The
single asterisk equals p<0.01, the double
asterisk equals p<0.001, and the triple
asterisk equals p<0.0001, using a two-
tailed Student's t-test assuming equal
variances. ND means “not determined.”
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nuclear counterstain (blue). Images were collected using Zeiss
Axiovision 4.4 software (Carl Zeiss, Oberkochen, Germany)
with a fixed exposure time, and all images were identically
post-processed with Adobe Photoshop (Adobe Systems, San
Jose, CA).
RESULTS
Control plasmids and normalization: The pFTM3GW LV
transfer vector (Figure 1) is an improved version of pFTMGW
[22] (see Methods for details). This vector utilizes a TB
element to greatly reduce expression (by 85%–90%) from the
hybrid hCMV/5′LTR (a promoter element required for in vitro
virus production). In each of the experiments presented here,
we utilize the low basal level of “read-through” expression
(~10%–15%) as our baseline for normalization, except for the
comparative expression in NIH/3T3 and Neuro-2a cells, for
which the pFUGW plasmid (containing a portion of the human
ubiquitin-C promoter) was used for normalization. Thus, the
percentage of eGFP positive cells counts for pFTMGW or
pFTM3GW control plasmids were assigned a value of 1.0, and
all measurements of experimental constructs are shown in
terms of fold change (in number of eGFP positive cells)
relative to pFTMGW, pFTM3GW, or pFUGW. In addition,
all MFI's were similarly normalized: these data are indicated
in each graph immediately under each bar (shaded with
orange). Lastly, the “leakiness” of the TB permits the
identification of putative repressive regulatory elements.
Müller cell-associated promoter testing: We systematically
examined the activity of 61 DNA sequences in the promoter
regions of 9 Müller cell-associated genes (Figure 2, Appendix
1). Fragments cloned from each gene are schematically
represented in Figure 2A, and numbered relative to the TSS.
We cloned the 500 bp and the 1500 bp sequences, both with
and without the adjacent 5′ UTR, for each of the nine genes
(Figure 2B-2J). In addition, ECRs were cloned with and
without the 5′ UTR. In some cases (CD44, GFAP, RLBP1,
and VIM; see Appendix 1), the most proximal ECR was not
immediately adjacent to the TSS: when cloning these ECR
+UTR fragments, additional intervening sequences
possessing less than our 70% homology threshold between the
ECRs and 5′ UTRs, including the TSSs, were included.
Finally, individual UTR sequences for seven of the nine genes
were tested alone. The UTRs for CAR2 (28 bp) and GFAP (14
bp) were quite small, and not individually examined.
Variable influences of the 5′ untranslated regions: In general,
the UTRs alone were capable of increasing the number of
Figure 3. The choice of gene promoter
and the presence of the gene’s 5′
untranslated region influence the level
of reporter gene expression in cultured
rat Müller cells. Microscopic analysis is
in agreement with the flow cytometry
data (Figure 2), and therefore serves as
a rapid, qualitative approach to
screening experimental promoters.
eGFP expression is demonstrated for the
500 bp promoter fragments either with
(right) or without (left) the 5′ UTR for
each of the nine genes analyzed (A-I).
Shown in (J) are control transfections
with the backbone vector (pFTM3GW;
left), or a vector containing the 1178 bp
human ubiquitin-C promoter (pFUGW;
right). Scale bar in (A) equals 10 µm.
Molecular Vision 2008; 14:691-705 <http://www.molvis.org/molvis/v14/a83> © 2008 Molecular Vision
695
eGFP positive cells two- to sevenfold (Figure 2). RLBP1
(Figure 2G) showed very low expression unless the UTR was
combined with other regulatory elements (500 bp, 1500 bp,
or ECR). Combining RLBP elements (500+UTR, 1500+UTR,
or ECR+UTR) resulted in greater than four- to sevenfold more
Müller cells expressing eGFP, with a concomitant increase in
MFIs (up to 3.6-fold higher; 500+UTR). Similarly for the
S100B gene (Figure 2H), including the UTR led to increased
expression over individual constructs. For S100B, the
combined constructs (500+UTR and ECR+UTR) appeared to
have more of an “additive” effect on eGFP expression,
whereas a “multiplicative” influence was apparent for
RLBP1. The UTRs of CD44 (Figure 2С) and PDGFRA
(Figure 2F) drove significant levels of eGFP expression on
their own, whereas the individual 5′ elements (500 bp, 1500
bp, and ECR) resulted in considerably lower eGFP
expression.
In contrast, some constructs without UTRs drove
significant levels of eGFP in cultured Müller cells. For
example, the 500 bp, 1500 bp, and ECR elements in CAR2
(Figure 2B), GFAP (Figure 2D; except ECR), GLUL (Figure
2E), and VIM (Figure 2J) resulted in three- to eightfold
changes in the number of cells expressing eGFP. Note that the
118 bp GLUL UTR led to a nominal (approximately twofold)
change in reporter gene expression by itself, whereas the
individual constructs (with or without the UTR) resulted in
six- to eightfold increases. Thus, in the case of GLUL, the UTR
appeared to exhibit only a minor influence on gene expression,
whereas upstream elements contributed significantly.
Constructs isolated from the SLC1A3 gene exhibited variable
influences on eGFP expression (Figure 2I). In contrast to other
genes, the SLC1A3 1500+UTR and 500+UTR sequences led
to reduced expression relative to the 500 bp and 1500 bp
fragments without the UTR (Figure 2I), suggesting a complex
cis-regulatory network involving both positive and negative
influences at the SLC1A3 promoter. Even though the cellular
specificity of these regulatory elements has not been verified,
it is worth noting that the short, 205 bp GFAP ECR+UTR
promoter fragment drove eGFP expression as well as any
other GFAP construct tested (Figure 2D).
Microscopic examination of 500 bp elements: We screened
promoter constructs using fluorescence microscopy before
flow cytometry analysis, and qualitatively assessed their
eGFP expression 24–40 h following transfection. Figure 3
shows fluorescent micrographs of rat Müller cells grown on
cover glass and transfected with the 500 bp and 500+UTR
constructs for each of the nine genes. Cultures were treated
identically to those used for flow cytometry experiments, and
qualitatively support the quantitative flow cytometry data
shown in Figure 2. The presence of the UTR enhanced the
number of eGFP-labeled cells in several experimental
constructs: CD44 (Figure 3B); PDGFRA (Figure 3E);
RLBP1 (Figure 3F); S100B (Figure 3G); and VIM (Figure 3I).
In contrast, little or no effect was observed for CAR2 (Figure
3A), GFAP (Figure 3C), or GLUL (Figure 3D). Lastly, the
presence of the UTR in the SLC1A3 construct (500+UTR;
Figure 3H) resulted in fewer eGFP labeled cells (also see
Figure 2I). Control transfections (Figure 3J) appropriately
exhibited a few dim (pFTM3GW) or numerous bright
Figure 4. Comparison of promoter
regulated gene expression in rat (wMC)
and human (MIO-M1) Müller cells.
Müller cells were transfected with 500
bp or 500+UTR genomic DNA
constructs (mouse) from each of the nine
genes analyzed. Expression was more
robust in rat Müller cells (red bars) when
compared with human MIO-M1 Müller
cells (blue bars), although the trends in
promoter-driven transgene expression
are similar between species and within
genes. Bars indicate fold change in
number of eGFP positive cells,
normalized to the promoter-less parent
vector (pFTM3GW). The mean
fluorescence intensity (MFI) for each
construct was also normalized to the
parent vector (pFTM3GW) and is
shown immediately below each bar
(shown in orange). Refer to Appendix
1 for genomic coordinates of each
construct. Error bars represent 1
standard deviation.
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(pFUGW; containing the human ubiquitin-C promoter)
fluorescent wMC Müller cells.
Comparison between rat and human Müller cells: To assess
orthologous promoter activity, we applied the same 500 bp
and 500+UTR promoter constructs to a spontaneously
generated human Müller cell line (MIO-M1 [36]). Figure 4
indicates fold changes in eGFP positive cells in both rat (red)
and human (blue) cultured Müller cells. All data were
normalized to the promoter-less parent plasmid, pFTM3GW
(not shown). As one might expect from divergent DNA
promoter sequences, the overall numbers (and MFIs) of eGFP
positive human Müller cells were reduced relative to the rat
(wMC) Müller cells. Importantly, though, the trends in the
data were notably conserved for several genes, suggesting that
some orthologous, sequence-related mechanisms are likely
participating in the reporter gene expression. Some genes
exhibit similar expression profiles (RLBP1, S100B,
SLC1A3), while others exhibit definitive differences (CAR2
and GFAP).
Further analysis of the mouse and rat CD44 and vimentin
promoters: We computationally identified, cloned, and
screened additional mouse and rat ECR sequences from the
CD44 and VIM genes. A total of 32 ECRs (see Appendix 2)
located both upstream and downstream (typically more distal
conserved regions) of the mouse and rat CD44 and VIM
coding sequences were cloned and studied by either flow
cytometry or fluorescence microscopy or both.
Approximately 60% (20/32) of the individual constructs
resulted in expression levels that were indistinguishable from
pFTMGW vector alone (see Appendix 2; constructs with “nd”
in the eGFP and MFI columns). After microscopic screening
(data not shown), the remaining ECRs (12/32) were analyzed
by flow cytometry (Figure 5; Appendix 2). Notably, some
ECRs representing the same conserved regions in mouse and
rat drove eGFP expression at similar expression levels (Figure
5; CD44M2/CD44R2 and VIMM2/VIMR2). Both pairs of
promoter constructs resulted in roughly two- to threefold
increases in number of eGFP expressing cells. Interestingly,
the two rodent VIM genes have different TSSs; VIMR2 (rat)
is a 409 bp fragment, containing 330 bp of the VIM promoter
and 79 bp of the VIM 5′ UTR, whereas VIMM2 (mouse) is
entirely within the VIM 5′ UTR. It is also important to notice
the reduction in the number of eGFP positive cells (and MFI)
by the VIMR6 and CD44R4 constructs. In particular, the
VIMR6 fragment negatively influenced eGFP expression by
both flow cytometry (Figure 5) and fluorescence microscopy
(data not shown). Moreover, when added to the VIMR2
promoter fragment, VIMR6 reduced the number of wMC
Müller cells by ~33% (Figure 6).
Complex and chimeric promoters are readily testable using
pFTMGW or pFTM3GW: We examined the feasibility of
cloning and testing in silico-designed, conjoined promoter
constructs (Figure 6). We added secondary ECRs to two
promising plasmid constructs containing VIMR2 or CD44R2
Figure 5. Transfection of mouse and rat
evolutionarily conserved regions from
the VIM and CD44 genes in wMC (rat)
Müller cells. Constructs containing
either 5′ (VIMM2, VIMR2, CD44M2,
CD44R2) or 3′ (VIMR7 and VIMR8)
UTRs exhibited high eGFP expression
levels (shown in bold). VIM constructs
are shown in red, and CD44 constructs
are shown in blue; lighter colors are
mouse constructs and darker colors are
rat constructs. Bars indicate fold change
in number of eGFP positive cells,
normalized to the “first-generation”
promoter-less parent vector
(pFTMGW). The mean fluorescence
intensity (MFI) for each construct was
also normalized to the parent vector
(pFTMGW) [22] and is shown
immediately below each bar (shown in
orange). Refer to Appendix 2 for
genomic coordinates of each construct.
The single asterisk equals p<0.01, the
double asterisk equals p<0.001, and the
triple asterisk equals p<0.0001, using a
two-tailed Student's t-test assuming
equal variances. Error bars represent 1
standard deviation.
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(both of rat origin). At least for VIMR2 and CD44R2, the
inclusion of additional ECR elements upstream of existing
elements (having already been cloned into the MCS) resulted
in a reduction in the number of eGFP expressing cells. The
chimeric construct, CD44R2 and VIMR2 (red-blue bar), was
not significantly different from either individual construct
with respect to number of eGFP positive cells or MFIs.
Duplicating the VIMR2 element slightly decreased the number
of cells, but did not affect the level of expression (MFI) when
compared to the single VIMR2 construct. Directional
selectivity/specificity of the VIMR2 promoter was confirmed
by testing a construct in which VIMR2 was cloned in the
opposite orientation (VIMR2-Reverse; 3′-5′ orientation). The
VIMR2-Reverse construct resulted in slightly fewer eGFP
positive cells (p=.033) when compared to the vector alone
(pFTMGW).
We also identified a short fragment from the rat vimentin
gene that appeared to negatively modulate transgene
expression when tested individually and when included in
combination with other putative regulatory elements. The
VIMR6 sequence lies ~2.8 kb upstream (5′) of the gene’s TSS,
and its specific function remains to be determined. Shown in
Figure 5, the 360 bp VIMR6 ECR fragment decreased the
amount of pFTMGW baseline expression by 45%, suggesting
Figure 6. Compound promoter constructs can modulate transgene expression. Vimentin (VIM) and CD44 evolutionary conserved regions
(ECRs) were tested were tested in various combinations. For both genes, we examined the effect of adding gene-specific ECRs to either of
the VIMR2 or CD44R2 element-containing vectors; in each case the added ECR was positioned 5′ to the existing cloned promoter element
(VIMR2 or CD44R2) within the multiple cloning site (MCS), to the, to the existing promoter element (VIMR2 or CD44R2). Adding VIMR2–
6 to the VIMR2-containing construct resulted in slightly lower number of cells expressing eGFP (shown in red), while the mean fluorescence
intensity (MFI) remained constant. When CD44R3–6 were individually added to CD44R2 (shown in blue), both cell counts and MFIs showed
a modest decrease. The VIMR2-Reverse reduced expression to near baseline levels. A chimeric promoter construct containing VIMR2 (3′)
and CD44R2 (5′) elements (red/blue) did not change expression significantly. Bars indicate fold change in number of eGFP positive cells,
normalized to the “first-generation” promoter-less parent vector (pFTMGW) [22]. The MFI for each construct was also normalized to the
parent vector (pFTMGW) and is shown immediately below each bar (shown in orange). Refer to Appendix 2 for genomic coordinates of each
construct. Compared to pFTMGW, all constructs (except VIMR2R) showed quantitatively different expression. p<0.01, using a two-tailed
Student's t-test assuming equal variances. The asterisk equals p<0.05, the double asterisk equals p<0.01, and the triple asterisk equals p<0.001,
using a two-tailed Student's t-test assuming equal variances. Error bars represent 1 standard deviation.
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that VIMR6 represents a putative inhibitory cis-regulatory
element. In Figure 6, we show that combining VIMR6 with
VIMR2 decreased the number of eGFP positive Müller cells
by nearly 30% (compared to VIMR2-only levels), adding
further evidence that VIMR6 has the capacity to mitigate gene
expression. However, note that VIMR6 did not decrease MFI
levels. For the CD44 gene, the CD44R4 construct exhibited
similar negative-modulating characteristics as VIMR6.
Comparison of expression in two non-glial cell types: Six
experimental constructs (GLUL 500±UTR, RLBP1
500±UTR, and S100b 500±UTR) were tested by transfection
in 3 cell types: wMC Muller cells, NIH/3T3 fibroblasts, and
Neuro-2a neuroblastoma cells (Figure 7). Both cell count and
MFI values for all constructs were normalized to pFUGW
expression levels. Under these culture conditions it is clear
that the promoter constructs tested do not restrict expression
to “glial” cells. After normalization to the pFUGW construct,
comparable percentages of cells (Figure 7A) and MFIs
(Figure 7B) were observed for wMC, NIH/3T3, and Neuro-2a
cells. Overall eGFP positive cell counts indicated that
Neuro-2a cells were significantly more receptive to
transfection, approaching 95% transfection efficiency
(compared to ~20% for both wMC and NIH/3T3 cells, using
an identical transfection protocol; data not shown). Most
Figure 7. Influence of cell type on
promoter-directed reporter gene
expression. Promoter constructs were
transfected into wMC (rat Müller cells;
red), NIH/3T3 (mouse fibroblasts;
green), or Neuro-2a (mouse
neuroblastoma; blue). All values were
normalized to pFUGW and plotted
according to percent enhanced green
fluorescent protein (eGFP) positive
cells (A) or mean fluorescence
intensities (MFI; B). A: Percent eGFP
expressing cells are plotted for control
(pFUGW, pFTMGW, and VMR2) and
xperimental (GLUL 500 ± untranslated
region (UTR), S100B 500±UTR, and
RLBP1 500±UTR) constructs. Note that
transfection efficiency of Neuro-2a cells
was significantly higher overall (95%
positive cells versus ~20% for wMC and
NIH/3T3), which, consequently,
resulted in significantly higher
expression in the pFTM3GW control.
Nevertheless, when normalized to
pFUGW, cell type had little influence on
the relative percentage of cells that
express eGFP, with the exception of a
doubling in the number of NIH/3T3
cells transfected with the RLBP1
500+UTR construct. B: Though
absolute eGFP expression levels were
quite different for the three cell types
examined, similar results to those in
(A) were obtained when the MFIs were
normalized to pFUGW. Perhaps an
overall trend is noticeable; NIH/3T3
cells (green) tended to offer slightly
higher relative eGFP expression, and
Neuro-2a cells (blue) tended to exhibit
slightly lower eGFP expression than
that observed for wMC Müller cells
(red). No TFX indicates no transfection.
Error bars represent 1 standard
deviation.
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notably, a distinct difference was observed when NIH/3T3
cells were transfected with the RLBP1 500+UTR construct,
which resulted in over twice as many cells becoming eGFP
positive, relative to the pFUGW control (Figure 7A). In
addition, it is noteworthy to point out that overall MFI levels
varied significantly for the three cell types: the average eGFP
intensities (arbitrary units) for the pFUGW constructs were
53.7, 9.7, and 86.5 for wMC, NIH/3T3, and Neuro-2a cells,
respectively. Thus, overall strength of transgene expression
appeared to be determined by the combination of promoter
activity and constitutive (undetermined) cellular qualities.
Nevertheless, when normalized to pFUGW, the trend with the
experimental constructs was that wMC cells expressed the
eGFP reporter molecule at intermediate levels, generally
between that of NIH/3T3 and Neuro-2a cells.
DISCUSSION
We believe that endogenous delivery of neuroprotective
molecules by Müller glia, by way of viral-mediated gene
transfer, holds significant promise for slowing the progression
of inherited retinal disease [37–39]. Neurotrophic factor
delivery is a broad, mutation-independent approach to
slowing the progression of neuronal cell loss in retinal damage
and disease [7,40,41]. An important consideration when
delivering genetically encoded molecules is how to properly
regulate and control their expression once delivered to the
nucleus of a targeted cell.
In an attempt to identify and initially characterize
functionally active regulatory elements capable of driving
transgene expression in Müller cells, we cloned promoter
constructs from nine Müller cell-associated genes into our
modified LV transfer vector, pFTM3GW (Figure 1). Our data
suggest that flow cytometry-based analysis of
computationally identified regulatory sequences is an
effective first step toward identifying small, gene-specific
promoters. Our data suggest that computationally identified
short ECR elements have the capacity to direct robust gene
expression, and that genetically diverse UTRs differentially
contribute to transgene expression. Finally, our data indicate
that combinatorial cloning of promoter fragments (from one
or more genes) may be exploited to facilitate fine-tuning of
therapeutic gene expression.
The RLBP1 and GLUL promoters exhibit robust gene
expression in our transfection assays. However, these two
genes, as an example, differ significantly with respect to the
influence of their respective UTRs. Only when the UTR is
combined with 5′ sequences (UTR+500, UTR+1500, or UTR
+ECR) do the RLBP1 constructs drive significant levels of
eGFP expression (Figure 2G). The number of eGFP
expressing cells and the MFIs of the combination constructs
are higher than the sum of the expression levels of the
individual elements. In contrast, the GLUL constructs were
minimally influenced by the inclusion of the UTR (only
slightly higher MFIs with the UTR; Figure 2E), and all
promoter constructs (with or without the associated UTR,
including a short 280 bp ECR) resulted in a high number of
eGFP positive cells. From these and other data, we conclude
that proximal regulatory and 5′ UTR sequences in and around
the gene’s “core promoter” likely operate in a gene-context
specific manner and have the capacity to function as more than
generic transcription initiation zones. Of course, it remains to
be determined how cell type specificity (of gene transcription)
is influenced by “promoter” shortening. We have shown
previously that shortening a promoter does not, a priori,
sacrifice gene expression specificity [22]. However, the
experiments presented here (Figure 7) suggest that, at least in
culture, glial-associated promoter elements do have the
capacity to express equally well in non-glial cell types, such
as NIH/3T3 fibroblasts and Neuro-2a neuroblastoma cells.
Analysis of CD44 and VIM ECRs indicates that promoter
activity can be modulated. Our data suggest that duplicating
(VIMR2/VIMR2) or combining (CD44R2/VIMR2) active
elements in the same construct does not result in higher
transgene expression, as we had originally hypothesized. On
the contrary, adding ECRs to functional promoter elements
(VIMR2 and CD44R2) appeared to reduce reporter gene
expression when compared to the single-element constructs
(Figure 6). In the case of the VIMR2/VIMR2 construct,
duplicating the same element actually reduced expression by
~15%, suggesting a possible competition for transcription
factor binding sites. It seems reasonable to hypothesize that
providing additional spacing between promoter elements
(including small “stuffer” sequences) may improve
accessibility of transcription factors, but this has yet to be
tested. It will be important to determine if individual ECRs
can be combined to increase transgene expression in future
studies.
Including the VIMR6 element in a combination construct
(VIMR6/VIMR2; Figure 6) also reduced reporter gene
expression, similar to the influence of this element on the
empty vector (Figure 5). These data suggest that VIMR6 may
function as a “partial repressor” and could conceivably be
included in future constructs to reduce expression levels of
active promoters. Importantly, reversing the orientation of the
VMR2 construct (VIMR2-Reverse; Figure 6) failed to drive
gene expression, reaffirming the expectation that promoter
orientation is critical for directed gene expression. Lastly, and
interestingly, 3′ UTR constructs from the VIM gene (VIMR7
and VIMR8) drove eGFP expression nearly as well as the 5′
UTR (VIMR2). Future experiments will test additional
combinations of ECRs, 5′ UTRs, and 3′ UTRs from other
genes, as well as the resultant cellular specificity of such
constructs. Thus, we believe that pFTM3GW is a powerful
tool that enhances our ability to examine multiple regulatory
elements in single promoter constructs, which will enable
detailed testing and analysis of in silico and in vitro engineered
regulatory constructs.
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We have shown previously [22] that quantification of
eGFP using flow cytometry is as accurate as quantitative RT–
PCR analysis. Moreover, flow cytometry analysis of
transfected cells is faster, cheaper, and less labor intensive
than quantitative RT–PCR, and therefore improves
quantitative throughput and analysis of promoter-regulated
gene expression. Importantly, though, microscopic screening
of transfected cells is a very rapid and reliable method to
quickly and qualitatively assess promoter strength (see Figure
3). Our transfection data suggest that 1) both 5′ and 3′ UTRs
can impart generally positive influences on gene expression;
2) short DNA sequences (500 bp or less) can drive expression
levels as robustly as the longer, canonical promoters; and 3)
combinations of regulatory elements can measurably
influence promoter activity. Future experiments will focus on
characterizing promoter cell-specificity and assessing the
concordance of expression levels between in vitro and in vivo
experimental assays.
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Appendix 1. Full-length and proximal promoter fluorescence data, genomic
fragment locations, and primer sequences.
To access the data, click or select the words “Appendix
1.” We identified and cloned the full-length promoters (~1500
bp), proximal promoter regions (~500 bp), the most proximal
evolutionarily conserved regions (ECRs) to the transcription
start site for each of nine genes identified in the literature as
being potential or known Müller cell markers: CAR2, CD44,
CRALBP, GFAP, GLUL, PDGFRA, S100B, SLC1A3, and
VIM. The sequences were cloned either including or excluding
the UTR, and then evaluated with fluorescent microscopy and
flow cytometry. The table shows the eGFP expression and the
mean fluorescent intensity, with values normalized and
expressed as fold change relative to pFTM3GW. Restriction
endonuclease is abbreviated REN. The “†” symbol identifies
small UTRs that were not individually tested. The “‡” symbol
denotes very large UTRs; only the ~200 bp regions
immediately following the TSS were analyzed. eGFP and MFI
values are shown as fold change relative to pFTM3GW vector
alone. An (R) denotes that gene is arranged in a “reversed”
orientation (3′-5′) relative to the chromosome’s centromere.
The “§” symbol denotes ECR not located immediately
proximal to the TSS, and some intervening sequence was
included in ECR+UTR constructs. “NM”numbers
immediately below the gene acronym refer to RefSeq mRNA
ID numbers.
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Appendix 2. Additional evolutionarily conserved region fluorescence data,
genomic fragment locations, and primer sequences.
To access the data, click or select the words “Appendix
2.” Additional evolutionarily conserved regions (ECR) from
CD44 and vimentin (VIM) were further studied; 32 sequences
were PCR amplified from C57BL/6J mouse and Sprague-
Dawley rat genomic DNAs, cloned into the pFTMGW vector,
and transfected into cultured rat Müller cells. The sequences
were initially screened by fluorescence microscopy.
Subsequently, eGFP positive constructs were analyzed by
flow cytometry. The table shows the eGFP expression and the
mean fluorescent intensity (MFI), with values normalized and
expressed as fold change relative to pFTMGW alone.
Restriction endonuclease is abbreviated REN. The “†” symbol
identifies referenced in Geller et al. (2007) [22] as Vim409.
The “‡” (nd) denotes flow cytometry was not performed on
constructs showing eGFP expression qualitatively similar to
vector (pFTMGW) alone. eGFP and MFI values are shown as
fold change in expression relative to pFTMGW vector alone.
An (R) denotes that gene is arranged in a “reversed”
orientation (3′-5′) relative to the chromosome’s centromere.
The “#” symbol represents that tested in combination with
VIMR2 or CD44R2; Figure 6. The “^” symbol denotes cloned
and tested in reverse orientation; Figure 6. The “@” denotes
sequence includes the 5′ UTR, the first protein coding exon,
and part of the first intron. “NM” numbers immediately below
the gene acronym refer to RefSeq mRNA ID numbers.
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